Individuals living with HIV who are optimally treated with combination antiretroviral therapy
(cART) can now lead an extended life. In spite of this remarkable survival benefit from viral …

Nowadays, HIV+ patients have an expected lifespan that is only slightly shorter than healthy
individuals. For this reason, along with the fact that infection can be acquired at a relatively …

Objectives: This is a cross-sectional, observational study to determine the frequency and
associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse …

Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and
mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders …

HIV-associated dementia (HAD) is an important complication of the central nervous system
in patients who are infected with HIV-1. Although the incidence of HAD has markedly …

Objective To evaluate whether penetration of a combination regimen into the central
nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is …

Approximately 40 million people worldwide are infected with human immunodeficiency virus
(HIV). Despite HIV's known propensity to infect the CNS and cause neurological disease …

Objective: To determine whether antiretroviral regimens with good central nervous system
(CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition. Design …

Objective: Although highly active antiretroviral therapy (HAART) can reverse HIV-related
neurocognitive impairment (NCI), neuropsychologic (NP) deficits may persist in a substantial …

HIV-associated central nervous system (CNS) injury continues to be clinically significant in
the modern era of HIV infection and therapy. A substantial proportion of patients with …